Saturday 11 April 2026

Pharma & Biotech Start-up & Scale-up News

Featured

Fate Therapeutics
A clinical-stage biopharmaceutical company developing first-in-class programmed off-the-shelf cellular immunotherapies for cancer and autoimmune diseases.
Biotechnology
Biocytogen inks antibody deal with BeOne, expanding strategic ties
10 July 2025
article
IDEAYA exercises option for license on Biocytogen’s IDE034
11 November 2024

Latest Ones To Watch News

Pharmaceutical
Annovis secures financing for buntanetap’s NDA submission
10 April 2026
Biotechnology
Alligator Bioscience links up with Unicancer on mitazalimab
10 April 2026
Biotechnology
Boehringer and BioNTech collaborate on SCLC trial of obrixtamig combo
10 April 2026
More ones to watch news >
Reset all filters
Refine search
Cue Biopharma
Cue Biopharma
Soleno Therapeutics
Soleno Therapeutics
MoonLake Immunotherapeutics
Excellergy
Terns Pharmaceuticals
Karyopharm Therapeutics
Rhythm Pharmaceuticals
Ovid Therapeutics
Alto Neuroscience
Purple Biotech
BeOne Medicines
Medicus Pharma
Antengene
Priovant Therapeutics
Abcuro
Protara Therapeutics
Ocular Therapeutix
Sensorion
Artios Pharma
Disc Medicine


Today's issue

MHRA approves Tryngolza for FCS
Pharmaceutical
MHRA approves Tryngolza for FCS
11 April 2026
Pharmaceutical
Boehringer hands CT-155 rights to Click in schizophrenia pivot
10 April 2026
Biotechnology
Daiichi taps Imagene to sharpen cancer biomarker discovery
10 April 2026
Pharmaceutical
Annovis secures financing for buntanetap’s NDA submission
10 April 2026
Pharmaceutical
Tempus AI expands collaboration with Gilead
10 April 2026
Pharmaceutical
Medicines Australia firmly opposes US tariffs on pharmaceuticals
10 April 2026
Biotechnology
Alligator Bioscience links up with Unicancer on mitazalimab
10 April 2026


Company Spotlight

A clinical-stage biopharmaceutical company developing first-in-class programmed off-the-shelf cellular immunotherapies for cancer and autoimmune diseases.




Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze